Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis

Abstract

This study provides Class I evidence that for patients with gMG, nipocalimab was well-tolerated, and it did not significantly improve MG-ADL at any individual dose but demonstrated a significant dose response for improved MG-ADL across doses.